Los Angeles Capital Management LLC Acquires Shares of 6,904 Apogee Therapeutics, Inc. (NASDAQ:APGE)

Los Angeles Capital Management LLC acquired a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,904 shares of the company’s stock, valued at approximately $272,000.

A number of other hedge funds have also recently bought and sold shares of APGE. Arizona State Retirement System grew its position in shares of Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after acquiring an additional 258 shares in the last quarter. EntryPoint Capital LLC grew its position in shares of Apogee Therapeutics by 44.7% in the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after acquiring an additional 617 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Apogee Therapeutics by 26.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after acquiring an additional 1,340 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Apogee Therapeutics by 28.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company’s stock worth $475,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after acquiring an additional 2,172 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Apogee Therapeutics Trading Up 4.5 %

Shares of APGE opened at $51.38 on Monday. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -9.79 and a beta of 2.74. The stock has a 50 day moving average of $46.97 and a 200-day moving average of $49.70. Apogee Therapeutics, Inc. has a 52 week low of $14.19 and a 52 week high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). On average, sell-side analysts predict that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares in the company, valued at approximately $11,084,216.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Michael Thomas Henderson sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the completion of the transaction, the chief executive officer now owns 1,394,487 shares in the company, valued at approximately $66,405,470.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now owns 294,793 shares of the company’s stock, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. Insiders sold 120,995 shares of company stock worth $5,218,774 in the last 90 days. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.